US Patent Issued to Blueprint Medicines on Feb. 17 for "Pyrrolotriazine derivatives for treating kit-and PDGFRA-mediated diseases" (Massachusetts Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,552,795, issued on Feb. 17, was assigned to Blueprint Medicines Corp. (Cambridge, Mass.).

"Pyrrolotriazine derivatives for treating kit-and PDGFRA-mediated diseases" was invented by Joseph L. Kim (Cambridge, Mass.), Thomas A. Dineen (Cambridge, Mass.) and Timothy Guzi (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and/or solvates of any of the foregoing which are useful for treating diseases and conditions related to mutant KIT and PDGFRa and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant K...